Physician profile
Faisal Nabi
NPI 1356382816
$8,454.72
in general payments reported to CMS, 2019-2025
29 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $263 · 2021: $414 · 2022: $3,951 · 2023: $698 · 2024: $1,852 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908 · Travel and Lodging: $815 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.91 |
| Travel and Lodging | $815.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $2,800.88 | 2019-2023 | Magnetom Sola, Naeotom Alpha |
| Heartflow, INC. | $1,972.90 | 2019-2025 | Ffrct |
| Philips North America LLC | $753.77 | 2022 | |
| Amgen INC. | $594.15 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $354.00 | 2019-2020 | |
| Pfizer INC. | $223.88 | 2019-2024 | |
| Ge Healthcare | $210.85 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $185.78 | 2022 | |
| Astellas Pharma US INC | $151.35 | 2019-2022 | |
| Edwards Lifesciences Corporation | $150.94 | 2025 | Sapien 3 Ultra Resilia |
| Cleerly, INC. | $135.78 | 2023 | Cleerly Labs |
| Esperion Therapeutics, INC. | $120.88 | 2022 | |
| W. L. Gore & Associates, INC. | $110.74 | 2021-2022 | |
| Endologix LLC | $100.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $97.74 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $77.22 | 2022 | |
| Bridgebio Pharma, INC. | $74.53 | 2025 | Attruby |
| Canon Medical Systems USA, INC. | $67.51 | 2019 | |
| Lantheus Medical Imaging, INC. | $50.87 | 2023 | Definity |
| Bracco Diagnostics INC. | $36.04 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $32.52 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $26.74 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.29 | 2025 | Lifevest |
| Boston Scientific Corporation | $21.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.32 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2023 | Jardiance |
| Vifor Pharma, INC. | $15.73 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.56 | 2019 | |
| Tactile Systems Technology INC | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Nabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.